Astellas VP-Business Development Masaki Doi: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
"The Pink Sheet" DAILY visited recently with Astellas Pharma VP-Business Development Masaki Doi at the company's headquarters in Tokyo to talk about the Japanese pharma's global licensing strategy and the changing paradigm of Japanese deal flow.
You may also be interested in...
Death Reported In Phase II Trial For Astellas/FibroGen's Oral EPO Candidate
Astellas/FibroGen have observed one fatality in a Phase II trial of the oral anemia treatment candidate FG-2216, Astellas reported May 7. The cause of death was fulminant hepatitis, and FDA has been notified
Death Reported In Phase II Trial For Astellas/FibroGen's Oral EPO Candidate
Astellas/FibroGen have observed one fatality in a Phase II trial of the oral anemia treatment candidate FG-2216, Astellas reported May 7. The cause of death was fulminant hepatitis, and FDA has been notified
Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.